Stemlfe – Slight improve of performance

Stemlfe registered est. 15% increase in revenue but 1.84 cents EPS. Which over RM 2 mil. from other income.  We dont consider other income as performance as it may means many things.  Taking out other income we see a slight increase in cost as well.  Therefore probably only 5% increase in profit.  We think is ok but we think there is a need for Stemlfe to look into other new innovative health science. Stem cell is good but with new biz is definitely always a good biz model R&D for new channels of income.